Sustained Virologic Response Rates of Sofosbuvir and Velpatasvir in Patients with Hepatitis C Genotype 3: A Meta-Analysis
| Author | Xi Ran | en |
| Author | HuaiYi Xie | en |
| Author | Wei Li | en |
| Orcid | Wei Li [0000-0002-7772-2525] | en |
| Issued Date | 2020-01-31 | en |
| Abstract | Context: Patients with hepatitis C virus (HCV) genotype 3 are regarded as a difficult-to-cure population in an era of direct-acting antiviral treatment. Objectives: This meta-analysis aimed to evaluate sustained virologic response rates resulting from a fixed-dose combination of sofosbuvir (SOF) and velpatasvir (VEL), also known as Epclusa® (Gilead, Forster City, CA) in patients with HCV genotype 3. Methods: In this study, we searched PubMed/MEDLINE, Embase, and the Cochrane Library for relevant studies from inception until May 3rd, 2019. The primary outcome measure used was the rate of the sustained virological response at week-12 (SVR12) post-treatment. The heterogeneity of results was evaluated, and influence analyses were performed using the R software. In addition, publication bias was assessed using the funnel and Egger tests. Results: Eleven trials (n = 2246 patients) were included in this meta-analysis. The pooled SVR12 rate in patients with HCV-genotype 3 (GT3) was 94.6% with a random effect model by inverse method (95% Cl 92.5% - 96.1%, I2 = 53%, P = 0.02). A subpopulation analysis indicated that the pooled SVR12 rates were 96.3% in GT3 patients with compensated cirrhosis and 94.0% in GT3 patients with prior anti-HCV treatment. Moreover, influence analysis suggested that the most significant source of heterogeneities resulted from one trial, which enrolled most patients with HCV subtype 3b. Conclusions: Our meta-analysis showed a high SVR12 rate of SOF/VEL in GT3 patients regardless of compensated cirrhosis the status and/or a history of previous interferon-based treatments. These results highlight the need for more trials investigating the effectiveness of the SOF/VEL regimen in patients with HCV subtype 3b. | en |
| DOI | https://doi.org/10.5812/hepatmon.98798 | en |
| Keyword | Sofosbuvir | en |
| Keyword | Velpatasvir | en |
| Keyword | HCV | en |
| Keyword | Genotype 3 | en |
| Keyword | SVR12 | en |
| Keyword | Meta-Analysis | en |
| Keyword | Cirrhosis | en |
| Publisher | Brieflands | en |
| Title | Sustained Virologic Response Rates of Sofosbuvir and Velpatasvir in Patients with Hepatitis C Genotype 3: A Meta-Analysis | en |
| Type | Systematic Review | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- hepatmon-20-1-98798.pdf
- Size:
- 715.63 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF